Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Randomized, Multicenter Study of IMC-A12 as a Single Agent or in Combination With Antiestrogens in Postmenopausal Women With Hormone Receptor-Positive Advanced or Metastatic Breast Cancer After Progression on Antiestrogen Therapy

NCT00728949 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT00728949
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00728949 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Randomized, Multicenter Study of IMC-A12 as a Single Agent or in Combination With Antiestrogens in Postmenopausal Women With Hormone Receptor-Positive Advanced or Metastatic Breast Cancer After Progression on Antiestrogen Therapy
Lead sponsor
Eli Lilly and Company
Phase
Phase 2
Overall status
Completed
Start date
August 31, 2008
Completion date
February 28, 2015
Enrollment
93 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic breast cancer